Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 11, 2008, Pages 1055-1062

  Sarlette, Alexander ^a   Krampfl, Klaus ^a   Grothe, Claudia ^b   Neuhoff, Nils Von ^a   Dengler, Reinhard ^a   Petri, Susanne ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Departments of Neuroanatomy   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Keap1; Motor neuron death; Neurodegenerative disease; Nrf2; Oxidative stress

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; TRANSCRIPTION FACTOR NRF2; GLIAL FIBRILLARY ACIDIC PROTEIN; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MOTONEURON; MOTOR CORTEX; NERVE CELL DEGENERATION; NERVOUS TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPINAL CORD; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MOTOR CORTEX; MOTOR NEURONS; NF-E2-RELATED FACTOR 2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 58149232639     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31818b4906     Document Type: Article

References (32)

1. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-75 (Pubitemid 24227760)
2. Aguirre N, Beal MF, Matson WR, Bogdanov MB. Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radic Res 2005;39:383-88
3. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr. Increased 3-nitrotyrosine in both sporadic and familial amyo-trophic lateral sclerosis. Ann Neurol 1997;42:644-54
4. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-74
5. Ferrante RJ, Shinobu LA, Schulz JB, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurology 1997;42:326-34
6. Perluigi M, Fai Poon H, Hensley K, et al. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic miceVa model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 2005;38:960-68 (Pubitemid 40321087)
7. Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 2005;58:258-65
8. Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006;22: 40-49
9. Wu AS, Kiaei M, Aguirre N, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003;85:142-50
10. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-50
11. van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE Signalling pathway: Promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord 2005;4:267-81
12. Shih AY, Imbeault S, Barakauskas V, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005;280:22925-36
13. Kotlo KU, Yehiely F, Efimova E, et al. Nrf2 is an inhibitor of the Fas pathway as identified by Achilles- Heel Method, a new function-based approach to gene identification in human cells. Oncogene 2003;22: 797-806
14. Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astro-cytes conditions neurons against oxidative insult. J Neurosci 2004;24: 1101-12
15. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleo-tide microarray analysis. J Biol Chem 2003;278:12029-38
16. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86
17. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: Oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004;24: 8477-86
18. Dinkova-Kostova AT, Holtzclaw WD, Wakabayashi N. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 2005;44:6889-99
19. Bloom DA, Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response elementY mediated NAD(P)H: Quinone oxidoreductase-1 gene expression. J Biol Chem 2003;278:44675-82
20. Numazawa S, Ishikawa M, Yoshida A, Tanaka S, Yoshida T. Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol 2003;285:C334-42
21. Ramsey CP, Glass CA, Montgomery MB, et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007;66:75-85
22. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005; 102:4584-89
23. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-99
24. Petri S, Krampfl K, Hashemi F, et al. Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J Neuropathol Exp Neurol 2003;62:1041-51
25. Wisden W, McNaughton LA, Darlison MG, Hunt SP, Barnard EA. Differential distribution of GABAA receptor mRNAs in bovine cerebellumYlocalization of alpha 2 mRNA in Bergmann glia layer. Neurosci Lett 1989e;106:7-12
26. Akbarian S, Huntsman MM, Kim JJ, et al. GABAA receptor subunit gene expression in human prefrontal cortex: Comparison of schizophrenics and controls. Cereb Cortex 1995;5:550-60
27. Suh JH, Shenvi SV, Dixon BM, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A 2004;101:3381-86
28. Pehar M, Vargas MR, Robinson KM, et al. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptorYinduced motor neuron apoptosis. J Neurosci 2007;27:7777-85
29. Kirby J, Halligan E, Baptista MJ, et al. Mutant SOD1 alters the motor neuronal transcriptome: Implications for familial ALS. Brain 2005;128: 1686-706
30. Vargas MR, Pehar M, Cassina P, et al. Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: Consequences for motor neuron survival. J Biol Chem 2005;280:25571-79
31. Kraft AD, Resch JM, Johnson DA, Johnson JA. Activation of the Nrf2-ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1. Exp Neurol 2007;207: 107-17
32. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61:427-34